CHGCY
Price
$21.89
Change
-$0.73 (-3.23%)
Updated
Sep 25 closing price
Capitalization
73.57B
CMOPF
Price
$83.60
Change
+$8.60 (+11.47%)
Updated
Sep 16 closing price
Capitalization
1.28B
Interact to see
Advertisement

CHGCY vs CMOPF

Header iconCHGCY vs CMOPF Comparison
Open Charts CHGCY vs CMOPFBanner chart's image
Chugai Pharmaceutical
Price$21.89
Change-$0.73 (-3.23%)
Volume$369.35K
Capitalization73.57B
Cosmo Pharmaceuticals
Price$83.60
Change+$8.60 (+11.47%)
Volume$100
Capitalization1.28B
CHGCY vs CMOPF Comparison Chart in %
Loading...
CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHGCY vs. CMOPF commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHGCY is a Hold and CMOPF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CHGCY: $21.89 vs. CMOPF: $83.60)
Brand notoriety: CHGCY and CMOPF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: CHGCY: 206% vs. CMOPF: 63%
Market capitalization -- CHGCY: $73.57B vs. CMOPF: $1.28B
CHGCY [@Pharmaceuticals: Major] is valued at $73.57B. CMOPF’s [@Pharmaceuticals: Major] market capitalization is $1.28B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $640.6B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHGCY’s FA Score shows that 1 FA rating(s) are green whileCMOPF’s FA Score has 1 green FA rating(s).

  • CHGCY’s FA Score: 1 green, 4 red.
  • CMOPF’s FA Score: 1 green, 4 red.
According to our system of comparison, CMOPF is a better buy in the long-term than CHGCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHGCY’s TA Score shows that 4 TA indicator(s) are bullish while CMOPF’s TA Score has 2 bullish TA indicator(s).

  • CHGCY’s TA Score: 4 bullish, 5 bearish.
  • CMOPF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, CMOPF is a better buy in the short-term than CHGCY.

Price Growth

CHGCY (@Pharmaceuticals: Major) experienced а -4.87% price change this week, while CMOPF (@Pharmaceuticals: Major) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.07%. For the same industry, the average monthly price growth was -0.30%, and the average quarterly price growth was +12.81%.

Industries' Descriptions

@Pharmaceuticals: Major (-1.07% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHGCY($73.6B) has a higher market cap than CMOPF($1.28B). CHGCY has higher P/E ratio than CMOPF: CHGCY (26.90) vs CMOPF (19.83). CMOPF YTD gains are higher at: 24.916 vs. CHGCY (-0.364). CHGCY has higher annual earnings (EBITDA): 556B vs. CMOPF (84.7M). CHGCY has more cash in the bank: 1.03T vs. CMOPF (127M). CHGCY has higher revenues than CMOPF: CHGCY (1.2T) vs CMOPF (182M).
CHGCYCMOPFCHGCY / CMOPF
Capitalization73.6B1.28B5,754%
EBITDA556B84.7M656,434%
Gain YTD-0.36424.916-1%
P/E Ratio26.9019.83136%
Revenue1.2T182M657,143%
Total Cash1.03T127M809,449%
Total DebtN/A2.7M-
FUNDAMENTALS RATINGS
CHGCY vs CMOPF: Fundamental Ratings
CHGCY
CMOPF
OUTLOOK RATING
1..100
1346
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
18
Undervalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9861
PRICE GROWTH RATING
1..100
5944
P/E GROWTH RATING
1..100
6847
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMOPF's Valuation (18) in the null industry is in the same range as CHGCY (25). This means that CMOPF’s stock grew similarly to CHGCY’s over the last 12 months.

CHGCY's Profit vs Risk Rating (92) in the null industry is in the same range as CMOPF (100). This means that CHGCY’s stock grew similarly to CMOPF’s over the last 12 months.

CMOPF's SMR Rating (61) in the null industry is somewhat better than the same rating for CHGCY (98). This means that CMOPF’s stock grew somewhat faster than CHGCY’s over the last 12 months.

CMOPF's Price Growth Rating (44) in the null industry is in the same range as CHGCY (59). This means that CMOPF’s stock grew similarly to CHGCY’s over the last 12 months.

CMOPF's P/E Growth Rating (47) in the null industry is in the same range as CHGCY (68). This means that CMOPF’s stock grew similarly to CHGCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHGCYCMOPF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
14%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
22%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
24%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
26%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
6%
View a ticker or compare two or three
Interact to see
Advertisement
CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WMMAX16.47N/A
N/A
TETON Westwood Mighty Mites A
LADYX32.95N/A
N/A
Lord Abbett Developing Growth I
JMIGX32.84N/A
N/A
Jacob Discovery Fd Instl
CBDYX56.92N/A
N/A
Columbia Balanced Inst3
VCGRX23.91N/A
N/A
Virtus KAR Capital Growth R6

CHGCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHGCY has been loosely correlated with DSNKY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CHGCY jumps, then DSNKY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHGCY
1D Price
Change %
CHGCY100%
-3.23%
DSNKY - CHGCY
38%
Loosely correlated
-1.09%
OTSKY - CHGCY
32%
Poorly correlated
-1.99%
OPHLY - CHGCY
32%
Poorly correlated
-1.58%
CHGCF - CHGCY
28%
Poorly correlated
-3.50%
DSKYF - CHGCY
23%
Poorly correlated
-2.30%
More

CMOPF and

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
N/A
GSK - CMOPF
22%
Poorly correlated
-1.64%
NVS - CMOPF
21%
Poorly correlated
-0.63%
CHGCY - CMOPF
7%
Poorly correlated
-3.23%
DSNKY - CMOPF
5%
Poorly correlated
-1.09%
CSPCY - CMOPF
4%
Poorly correlated
-0.94%
More